U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Tuesday.The Dow traded up 0.22% to 48,469.41 while the NASDAQ rose 0.40% to 23,521.69. The S&P 500 also rose, gaining, 0.34% to 6,901.90.Check This Out: Meta Platforms To $815? Here Are 10 Top Analyst Forecasts For TuesdayLeading and Lagging SectorsCommunication services shares rose by 0.5% on Tuesday.In trading on Tuesday, consumer staples stocks fell by 0.5%.Top HeadlineU.S. durable goods orders decl ...

U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 0.2% on Tuesday.Following the market opening Tuesday, the Dow traded down 0.01% to 48,357.98 while the NASDAQ jumped 0.19% to 23,473.74. The S&P 500 also rose, gaining, 0.15% to 6,888.53.Check This Out: Meta Platforms To $815? Here Are 10 Top Analyst Forecasts For TuesdayLeading and Lagging SectorsCommunication services shares rose by 0.9% on Tuesday.In trading on Tuesday, consumer staples stocks fell by 0.4%.Top HeadlineU.S. GD ...

U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 0.2% on Tuesday.Following the market opening Tuesday, the Dow traded down 0.01% to 48,357.98 while the NASDAQ jumped 0.19% to 23,473.74. The S&P 500 also rose, gaining, 0.15% to 6,888.53.Check This Out: Meta Platforms To $815? Here Are 10 Top Analyst Forecasts For TuesdayLeading and Lagging SectorsCommunication services shares rose by 0.9% on Tuesday.In trading on Tuesday, consumer staples stocks fell by 0.4%.Top HeadlineU.S. GD ...

Core Insights - Trinity Biotech has reached a critical profitability inflection point and expects to be Adjusted EBITDA positive and cash flow positive starting Q3 2025 [1][5][10] - The company has undergone significant operational restructuring to reduce costs and improve efficiency, laying the groundwork for sustainable profitability [5][10] - Trinity Biotech is focusing on growth opportunities, including the international rollout of new products and the development of innovative diagnostic solutions [5][12] Financial Performance - For Q1 2025, Trinity Biotech reported revenue of $7.6 million, with a gross profit of $1.9 million and an operating loss of $6.5 million [10] - The company anticipates a significant increase in revenue for Q2 2025, projecting a range of approximately $11 million to $12 million due to ramped-up manufacturing and normalized demand for rapid HIV tests [10] - The company expects further revenue growth in Q3 2025, driven by the resumption of manufacturing and supply of its flagship rapid HIV test, TrinScreen HIV [10] Strategic Developments - The company is advancing its next-generation continuous glucose monitoring (CGM) solution, which is seen as a major growth opportunity in the $13 billion global CGM market [5] - Trinity Biotech is also progressing towards commercialization of key medium-term growth drivers, including a preeclampsia screening test and a prostate cancer test [5] - The company has completed a pre-pivotal trial on its upgraded sensor technology for the CGM solution and plans to unveil key aspects of this innovative design soon [5]